Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW.
Kereiakes DJ, et al. Among authors: runyon jp.
Am Heart J. 2000 Oct;140(4):603-10. doi: 10.1067/mhj.2000.109647.
Am Heart J. 2000.
PMID: 11011333